Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. The company's product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. Imugene is a publicly traded company, listed on the Australian Securities Exchange under the code IMU. In December 2021 it entered the S&P/ASX 200 Index, in effect making it one of the 200 largest companies on the ASX. Wikipedia